Medical School University of Mississippi School of Medicine Graduated: 1999
Languages:
English
Description:
Dr. Lewin graduated from the University of Mississippi School of Medicine in 1999. He works in Dallas, TX and specializes in Anatomic Pathology & Clinical Pathology. Dr. Lewin is affiliated with Pine Creek Medical Center.
Geoffrey D. Ralston - Menlo Park CA, US David H. Nakayama - Palo Alto CA, US Matthew E. Lewin - Santa Clara CA, US Ravichandran Menon Jayachandran - Sunnyvale CA, US Brian R. Woods - San Francisco CA, US Udi Manber - Palo Alto CA, US
Assignee:
Yahoo! Inc. - Santa Clara CA
International Classification:
H06F015/16
US Classification:
709206, 709207
Abstract:
The invention relates to processing of electronic text communication distributed in bulk. In one embodiment, a method for detecting electronic text communication distributed in bulk is disclosed. After receiving a first electronic text communication, it is processed with an algorithm to produce a first fingerprint. A time period is begun for the first electronic text communication. After receiving a second electronic text communications, it is also processed with the algorithm to produce a second fingerprint. The first fingerprint to the second fingerprint are compared to determine if the first electronic text communication is similar to the second electronic text communication. A count for the first electronic text communication is updated based upon the comparison. It is determined if the count during the time period reaches a first threshold.
Geoffrey D. Ralston - Menlo Park CA, US David H. Nakayama - Palo Alto CA, US Matthew E. Lewin - Santa Clara CA, US Ravichandran Menon Jayachandran - Sunnyvale CA, US Brian R. Woods - San Francisco CA, US Udi Manber - Palo Alto CA, US
Assignee:
Yahoo! Inc. - Sunnyvale CA
International Classification:
G06F 15/16
US Classification:
709206, 379 8822
Abstract:
The invention relates to processing similar electronic text communication. In one step, a first electronic and a second electronic submission, that are part of a plurality of electronic submissions, are received. A first portion is extracted from the first electronic submission and a second portion from the second electronic submission. Content of the first electronic submission influences extraction of the first portion and content of the second electronic submission influences extraction of the second portion. Locations for the first and second portions could vary with content. A first code is determined for the first portion and a second code for the second portion, where the first code is indicative of the first portion and the second code is indicative of the second portion. The first code to the second code are compared to associate the first and second electronic submission together.
Processing Of Textual Electronic Communication Distributed In Bulk
Geoffrey D. Ralston - Menlo Park CA, US David H. Nakayama - Palo Alto CA, US Matthew E. Lewin - Santa Clara CA, US Ravichandran Menon Jayachandran - Sunnyvale CA, US Brian R. Woods - San Francisco CA, US Udi Manber - Palo Alto CA, US
Assignee:
Yahoo ! Inc. - Santa Clara CA
International Classification:
G06F 1516
US Classification:
709206, 709207, 379 8
Abstract:
The invention relates to processing of electronic text communication distributed in bulk. In one embodiment, a process for blocking electronic text communication distributed in bulk is disclosed. In the process, a first electronic and a second electronic submission are received. A first portion is extracted from the first electronic submission and a second portion is extracted from the second electronic submission. A first code is determined for the first portion and a second code is determined for the second portion. The first code is indicative of the first portion and the second code is indicative of the second portion. After the first code is compared to the second code, the second electronic submission is filtered in response to that comparison.
Envenomation Therapies And Related Pharmaceutical Compositions, Systems And Kits
The invention provides methods of treatment, pharmaceutical compositions, systems and kits appropriate for first line and/or adjunct therapy with antivenom using at least one active component, in some instances at least two active components and in other instances no more than two active components selected from the group consisting of a selective secretory PLAinhibitor (sPLA2 or PLAinhibitor), a metalloproteinase inhibitor, a serine protease inhibitor, antivenom, one or more acetylcholinesterase inhibitors or a nAChR agonist paired with a mAChR antagonist, a NMDA receptor antagonist and a spreading factor inhibitor to treat a subject who suffers from an envenomation, preferably at the time of envenomation and often within a period of less than about an hour after an envenomation or 6 hours after an envenomation and throughout the course of treatment at time with or without anti-venom as an adjunct therapy after an envenomation by, for example, a snake or invertebrate.
Pla2 And Hmg-Coa Inhibitors For Treatment Of Pathological Conditions Causing Hemolysis, Cerebral Edema, And Acute Kidney Injury
- Corte Madera CA, US Matthew R. Lewin - Corte Madera CA, US
International Classification:
A61K 31/4045 A61K 31/192 A61K 45/06 A61P 39/02
Abstract:
Provided are methods for treatment of pathological conditions causing hemolysis, cerebral edema, acute kidney injury and non-anaphylactic shock, including envenomation, trauma, cerebral malaria and mast-cell diseases using at least one PLA2 inhibitor, alone or in combination with other agents. The unexpected versatility of PLA2 inhibitors, their dosage forms and combinations make them candidates as essential medicines for the developing world.
Envenomation Therapies And Related Pharmaceutical Compositions, Systems And Kits
The invention provides methods of treatment, pharmaceutical compositions, systems and kits appropriate for first line and/or adjunct therapy with antivenom using at least one active component, in some instances at least two active components and in other instances no more than two active components selected from the group consisting of a selective secretory PLAinhibitor (sPLA2 or PLAinhibitor), a metalloproteinase inhibitor, a serine protease inhibitor, antivenom, one or more acetylcholinesterase inhibitors or a nAChR agonist paired with a mAChR antagonist, a NMDA receptor antagonist and a spreading factor inhibitor to treat a subject who suffers from an envenomation, preferably at the time of envenomation and often within a period of less than about an hour after an envenomation or 6 hours after an envenomation and throughout the course of treatment at time with or without antivenom as an adjunct therapy after an envenomation by, for example, a snake or invertebrate.
Administration Of Acetylcholinesterase Inhibitors To Mitigate Neurotoxin-Induced Paralysis And Residual Neuromuscular Blockade
Matthew R. LEWIN - , US Matthew R. Lewin - Corte Madera CA, US
Assignee:
OPHIREX, INC. - Corte Madera CA
International Classification:
A61K 31/4425 A61K 9/00 A61K 31/40
Abstract:
Methods and kits for treating or reducing the likelihood of neurotoxin-induced respiratory failure in a subject, such as a victim of neurotoxic envenomation are provided. Also provided are methods for treating or reducing the likelihood of residual neuromuscular blockade in a subject to whom a nondepolarizing neuromuscular blocking agent has been administered. The methods involve administering a pharmaceutically effective dose of an acetylcholinesterase inhibitor to the subject, where the administration is not via injection. In some embodiments intra-nasal or ocular administration is used.
Name / Title
Company / Classification
Phones & Addresses
Matthew Robert Lewin
Matthew Lewin MD,PHD Emergency Medicine
180 Rowland Way, Novato, CA 94945 4152091350
Matthew R. Lewin Medical Doctor
Dr. Carey E. Levin, MD Medical Doctor's Office · Nonclassifiable Establishments